BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 28, 2008
 |  BioCentury  |  Product Development

Channeling to control T cells

Debiopharm S.A. has taken an option on a peptide that it believes may not only provide a therapeutic benefit in halting flare-ups in the acute treatment of autoimmune diseases, but also avoid the immune suppression associated with other therapies.

Airmid Inc. granted Debiopharm an option to worldwide rights to develop and commercialize Debio 0824, an ShK peptide analog that is a highly specific potassium (K) channel Kv1.3 blocker. It is in preclinical testing to treat autoimmune diseases such as psoriasis, multiple sclerosis (MS) and rheumatoid arthritis (RA).

ShK peptides are naturally occurring polypeptides found in...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >